Search Results - "Chalker, Cameron"

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients by Chalker, Cameron, Voutsinas, Jenna M., Wu, Qian Vicky, Santana‐Davila, Rafael, Hwang, Victoria, Baik, Christina S., Lee, Sylvia, Barber, Brittany, Futran, Neal D., Houlton, Jeffrey J., Laramore, George E., Liao, Jay Justin, Parvathaneni, Upendra, Martins, Renato G., Eaton, Keith D., Rodriguez, Cristina P.

“…Background Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell…”
Get full text

Use of PSMA PET/CT to detect prostate cancer metastatic to a preexisting thyroid nodule by Chalker, Cameron, Yilmaz, Burçak, Trone, Kristin, Parecki, Genevieve, Chen, Athena, Lim, James Y., Mallak, Nadine, Sokolova, Alexandra O.

“…Prostate cancer (PCa) seldom metastasizes to the thyroid gland, and only a limited number of cases are documented in the literature. The application of a…”
Get full text

Germline and somatic mutations in prostate cancer: Implications for treatment by Chalker, Cameron, Chun, Brie, Sokolova, Alexandra O.

“…Genetic testing is an integral part of the workup of metastatic prostate cancer, in part, because the results can have a profound impact on the subsequent…”
Get full text

Assessing Rural Disparities in Telemedicine Palliative Care Delivery for Patients with Cancer by Beeson, Erynn A., Chalker, Cameron, Lowry, Sarah, Devara, Tanuj, Joshi, Sonali, Lim, Jeong Y., Gold, Jeff, Roeland, Eric J.

“…1. Learners will describe how demographics are associated with the mode of clinical care delivery (in-person, virtual, or audio) for patients with advanced…”
Get full text

Impact of ECOG performance status on recurrent/metastatic head and neck squamous cell carcinomas treated with anti-PD1 inhibitors by Chalker, Cameron, Wu, Vicky, Voutsinas, Jenna M., Hwang, Victoria, Baik, Christina S, Liao, Jay Justin, Lee, Sylvia, Futran, Neal D., Houlton, Jeffrey, Barber, Brittany, Parvathaneni, Upendra, Laramore, George E., Santana-Davila, Rafael, Eaton, Keith D., Martins, Renato G., Rodriguez, Cristina P.

“…Abstract only e18004 Background: Anti-PD1 checkpoint inhibitors (ICI) represent an established standard of care for patients with recurrent/metastatic head &…”
Get full text

End-of-life health care utilization (EOLHCU) in patients with recurrent, metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with immune checkpoint inhibitors (IO) by Chalker, Cameron, Santana-Davila, Rafael, Voutsinas, Jenna M., Wu, Vicky, Hwang, Victoria, Baik, Christina S, Barber, Brittany, Futran, Neal D., Houlton, Jeffrey, Laramore, George E, Lee, Sylvia, Liao, Jay Justin, Parvathaneni, Upendra, Martins, Renato G., Eaton, Keith D., Rodriguez, Cristina P.

“…Abstract only e18516 Background: Demographic and EOLHCU trends are undefined in the growing population of IO-treated RMHNSCC; we sought to study these in a…”
Get full text

High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors by Chalker, Cameron, Santana-Davila, Rafael, Voutsinas, Jenna M, Wu, Qian Vicky, Hwang, Victoria, Baik, Christina S, Lee, Sylvia, Barber, Brittany, Futran, Neal D, Houlton, Jeffrey J, Laramore, George E, Liao, Jay Justin, Parvathaneni, Upendra, Martins, Renato G, Eaton, Keith D, Rodriguez, Cristina P

“…End-of-life health care utilization (EOLHCU) is largely uncharacterized among patients with recurrent/metastatic head and neck squamous cell carcinomas…”
Get more information